| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
BioLineRx Ltd.
$2.92
-0.08 (-2.83%)
D 38Pipeline Score Fair Value Pharma · Commercial
Market Cap
13.19 M
EPS
-0.18
P/E Ratio
-
Value Trade
23.95 K
5.99 %
Week
7.23 %
1 Month
-4.41 %
3 Month
9.84 %
6 Month
-97.62 %
5 Year
-99.92 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.40 K
52 Week Range
2.15 - 4.56
% held by Insiders
0.56 %
% held by Institutions
1.53 %
Enterprise Value
6.16 M
Total Shares
4.37 M
Short %
3.11 %
Float Shares
4.34 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioLineRx Ltd.
132Total events
5Upcoming
39Tier-1 (high impact)
2011 – 2027Coverage
Upcoming catalysts 2
TBD
T2Enrollment Complete
Subscribe to view catalyst details
TBD
T1Full Results
Subscribe to view catalyst details
Event history 2
TBD
▲Preclinical PoCGLIX1Preclinical
Subscribe to view catalyst details
TBD
◆Poster PresentationGLIX1Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2023-09-09 | APHEXDA | PDUFA Date | PDUFA | Approved | – | – | – |
2023-09-09 | APHEXDA | PDUFA Date | PDUFA | Approved | – | – | – |
2023-09-09 | APHEXDA | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
D38
Pipeline Score $37M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored3.0x
rNPV / MCap Top 59%
Micro Cap (rank 384 of 933)
Percentile RankBioLineRx Ltd. faces pipeline headwinds (38/100), with $1.9B risk-adjusted pipeline value, led by BL-8040/kg+ G-CSF in Multiple Myeloma (Phase 3), across $53B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL-8040/kg+ G-CSF Small molecule | Multiple Myeloma | Phase 3 | NCT03246529 | 42% | $968M | ACTIVE NOT_RECRUITING | 180 | STALLED | B (62) | Sep 30, 2029 | MODERATE_RISK | Jan 15, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
motixafortide | first-line pancreatic cancer | Phase 2 | 2025-05-30 | 64%; 4 of 11; 91%; 10/11; 23%; 48% | BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting Read More | |
motixafortide | first-line pancreatic cancer | Phase 2 | 2025-05-30 | 64%; 4 of 11; 91%; 10/11; 23%; 48% | BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting Read More | |
motixafortide | first-line pancreatic cancer | Phase 2 | 2025-05-30 | 64%; 4 of 11; 91%; 10/11; 23%; 48% | BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BLRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BLRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BLRX▼ -2.8%today
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx Ltd. will announce its unaudited financial results for Q2 2026 on August 31, 2026, before U.S. markets open. A conference call featuring CEO Philip Serlin will follow at 8:30 a.m. EDT. The company is focused on developing therapies for oncology and rare diseases, including its lead asset GLIX1.
Read more →BLRXBioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
BioLineRx and Hemispherian have announced promising preclinical data showing significant synergy between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The combination exhibited better efficacy than control and monotherapy arms, suggesting potential for broader use of PARP inhibitors in ovarian cancer treatment. This data supports the advancement of GLIX1 in clinical trials.
Read more →BLRX▲ +7%on this news· ran to +26% by day 3
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and Hemispherian AS announced that two abstracts on GLIX1 will be presented at the ASCO 2026 Annual Meeting. This collaboration highlights their commitment to developing innovative therapies in oncology. The meeting will take place from May 29 to June 2, 2026, in Chicago, IL.
Read more →BLRXBioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx Ltd. will announce its unaudited financial results for Q1 2026 on May 27, 2026. A conference call featuring CEO Philip Serlin will follow at 8:30 a.m. EDT. The company is advancing its lead asset GLIX1 in a Phase 1/2a trial and has ongoing collaborations for other products.
Read more →BLRXBioLineRx to Report 2025 Annual Results on March 23, 2026
BioLineRx Ltd. will announce its audited financial results for the year ending December 31, 2025, on March 23, 2026. A conference call featuring CEO Philip Serlin will take place at 8:30 a.m. EDT. The company is advancing its clinical pipeline, including the upcoming Phase 1/2a trial for GLIX1.
Read more →BLRX▲ +38.5%on this news
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx announced promising new data from the pilot phase of its CheMo4METPANC Phase 2 combination trial for first-line pancreatic cancer, with results to be presented at ASCO 2025. The trial evaluates motixafortide, cemiplimab, and standard chemotherapies, showing an overall response rate of 64% and four out of eleven patients remaining progression-free after more than one year. Updates reveal significant increases in CD8+ T-cell tumor infiltration, underscoring the potential of this combination therapy in treating a historically challenging cancer type. The study will expand enrollment in response to these encouraging findings.
Read more →BLRX▲ +7.4%on this news
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
BioLineRx Ltd. has announced the U.S. Patent and Trademark Office's allowance of a new composition of matter patent covering motixafortide, enhancing their intellectual property and extending patent protection until December 2041. The CEO highlighted the significance of this patent in recognizing motixafortide as a key advancement for multiple myeloma patients and other high-need indications. BioLineRx has also secured orphan drug market exclusivity for motixafortide and various international patents, bolstering their competitive position in the biopharmaceutical market.
Read more →BLRXBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
BioLineRx Ltd. announced the drawdown of the second tranche of $20 million from a $40 million non-dilutive debt financing agreement with BlackRock. The funds are earmarked to enhance the commercialization of APHEXDA for multiple myeloma and to support programs in sickle cell disease and metastatic pancreatic cancer. The detailed terms of the agreement were set out in a previous announcement from September 2022, which included favorable terms for the company. BioLineRx also reiterated its future milestones, including the expansion efforts in Asia and ongoing clinical trials.
Read more →BLRXBioLineRx to Report 2023 Annual Financial Results on March 26, 2024
BioLineRx Ltd. will announce its audited financial results for the year ending December 31, 2023, on March 26, 2024. The company will hold a conference call at 08:30 a.m. EDT, featuring remarks from CEO Philip Serlin. This event underscores the company's commitment to transparency and investor engagement.
Read more →BLRXBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
BioLineRx has finalized an exclusive licensing agreement with Guangzhou Gloria Biosciences for the development of motixafortide in Asia. The deal includes a $15 million upfront payment and potential milestones totaling up to $250 million. Gloria Biosciences will initiate a bridging study for stem cell mobilization and a Phase 2/3 trial for pancreatic cancer. This partnership aims to address significant unmet medical needs in the region.
Read more →BLRXBioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
BioLineRx announced promising results from the pilot phase of its Phase 2 clinical trial for motixafortide in first-line pancreatic cancer. Out of 11 patients, 6 experienced a partial response, with 4 confirmed cases. The trial aims to evaluate the combination of motixafortide with standard chemotherapy and PD-1 inhibitors. The findings were presented at the AACR Special Conference on Pancreatic Cancer.
Read more →BLRXBioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma | BioLineRx
BioLineRx announced FDA approval of APHEXDA™ (motixafortide) in combination with filgrastim for mobilizing hematopoietic stem cells in multiple myeloma patients. This marks the first innovation in stem cell mobilization in the U.S. in a decade, with significant efficacy demonstrated in clinical trials.
Read more →BLRXBioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx reported its second quarter 2023 financial results, highlighting significant progress in its clinical pipeline. The company is on track for a PDUFA target action date for Motixafortide in stem cell mobilization. Additionally, BioLineRx signed an exclusive license agreement for Motixafortide in Asia and initiated a Phase 2 trial for pancreatic cancer. The CEO expressed optimism for the company's future as it transitions towards commercialization.
Read more →BLRXBioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. reported its first quarter 2023 financial results and provided updates on its pipeline, primarily focusing on motixafortide. The company is on track for a September 9, 2023 PDUFA date for this product targeting stem cell mobilization in multiple myeloma. In addition, BioLineRx announced positive Phase 3 trial results published in Nature Medicine and is gearing up for a potential U.S. launch. The company also highlighted advancements in their oncology programs, including motixafortide's use in metastatic pancreatic cancer and gene therapy for sickle cell disease.
Read more →BLRXBioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
BioLineRx announced the publication of its GENESIS Phase 3 trial data in Nature Medicine, showing that motixafortide combined with G-CSF significantly improves stem cell mobilization in multiple myeloma patients prior to autologous transplantation. The trial met all primary and secondary endpoints with high statistical significance. This publication highlights the potential of motixafortide to address clinical challenges in stem cell mobilization.
Read more →BLRXBioLineRx to Report 2022 Annual Financial Results on March 22, 2023
BioLineRx Ltd. will release its audited financial results for the year ended December 31, 2022, on March 22, 2023, before U.S. markets open. The company's CEO, Philip Serlin, will host a conference call at 10:00 a.m. EDT on the same day. BioLineRx focuses on oncology, with promising developments including a pending NDA submission for its lead program, motixafortide, which has shown effectiveness in clinical trials for multiple myeloma and pancreatic cancer.
Read more →BLRXBioLineRx Ltd: Please contact the Portnoy Law Firm to recover your losses; March 6, 2023 deadline
The Portnoy Law Firm is advising investors of BioLineRx Ltd. (NASDAQ:BLRX) to contact them regarding a lawsuit for investors who purchased securities between February 23, 2021, and September 19, 2022. The lawsuit claims BioLineRx made false and misleading statements about its financial state and the development of its drug, Motixafortide. Allegations include the company's lack of sufficient funding and the need for a loan and securities offering, which misled investors and resulted in financial damages.
Read more →BLRXBioLineRx Ltd. (BLRX) Class Action Notice: Contact Robbins LLP for Information Regarding the Class Action Against BioLineRx Ltd. and Lead Plaintiff Deadline
Robbins LLP has announced a class action lawsuit for investors of BioLineRx Ltd. (BLRX) who acquired American depository shares between February 23, 2021, and September 19, 2022. The lawsuit alleges that BioLineRx misrepresented its financial health and the viability of its drug Motixafortide, a treatment intended for multiple myeloma. Following a critical announcement regarding a needed $40 million loan and securities offering, the company's stock plummeted by 33%. Shareholders have until March 6, 2023, to apply as lead plaintiffs in the case.
Read more →BLRXBioLineRx Ltd. (BLRX) Class Action Alert: Robbins LLP Urges Shareholders with Significant Losses in BioLineRx Ltd. to Contact the Firm
A class action lawsuit has been filed against BioLineRx Ltd. (BLRX) for allegedly misrepresenting its financial status and drug development plans concerning its lead candidate, Motixafortide. The complaint cites that, during the class period, the company falsely claimed it was financially capable of advancing its drugs, when in fact, it needed a substantial loan and securities offering to proceed. Following the announcement of the securities offering, BLRX's stock price fell by 33%. Shareholders can participate in the lawsuit and may recover losses without being involved in the case.
Read more →BLRXBioLineRx Ltd. (BLRX) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against BioLineRx Ltd.
Robbins LLP has alerted investors about a class action lawsuit against BioLineRx Ltd. (BLRX), filed on behalf of shareholders who acquired ADSs between February 23, 2021, and September 19, 2022. The lawsuit claims that the company misrepresented its financial stability and ability to develop its lead product candidate, Motixafortide. Following the announcement of a $15 million securities offering to support the drug's launch, the company's stock plummeted by 33%. Shareholders interested in participating in the class action must file by March 6, 2023.
Read more →BLRXBioLineRx Class Action Alert: Submit Your Losses to Johnson Fistel
A class action lawsuit has been filed against BioLineRx Ltd. on behalf of investors who purchased securities between February 23, 2021, and September 19, 2022. The lawsuit alleges that BioLineRx made misleading statements about its financial situation and the development of its drug, Motixafortide. Claims indicate that the company misrepresented its ability to fund development while also needing loans and additional securities offerings. Investors have until March 6, 2023, to apply to be the lead plaintiff in this case.
Read more →BLRXBioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, Nov. 4, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the
Read more →BLRXBioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter
TEL AVIV, Israel, Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten offering of 14,375,000 American Depositary Shares
Read more →BLRXBioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
TEL AVIV, Israel, Jan. 14, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European Commission (EC) has granted Orphan Drug Designation to its lead oncology candidate, Motixa
Read more →BLRXBioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
TEL AVIV, Israel, Feb. 4, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead oncology can
Read more →BLRXBioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
TEL AVIV, Israel, Dec. 11, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in pati
Read more →BLRXBioLineRx to Report Third Quarter 2018 Results on November 8, 2018
TEL AVIV, Israel, November 1, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended September 30, 2018
Read more →BLRXBioLineRx Reports First Quarter 2018 Financial Results
TEL AVIV, Israel, May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2018. Highlights and achievements d
Read more →BLRXBioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
TEL AVIV, Israel, Jan. 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study showing that
Read more →BLRXBioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
TEL AVIV, Israel, Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY. Philip
Read more →BLRXBioLineRx Reports Third Quarter 2017 Financial Results
TEL AVIV, Israel, Nov. 21, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017. Highlights and achievements duri
Read more →BLRXBioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
TEL AVIV, Israel, September 7, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Ma
Read more →BLRXBioLineRx Reports Second Quarter 2017 Financial Results
TEL AVIV, Israel, Aug. 8, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2017. Highlights and achievements during th
Read more →BLRXBioLineRx to Report Second Quarter 2017 Results on August 8, 2017
TEL AVIV, Israel, August 2, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended June 30, 2017 on
Read more →BLRXBioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares Tel Aviv , Israel
Closes $28.75 Million Underwritten Public Offering Tel Aviv, Israel - April 5, 2017 - BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has closed its previously announced unde
Read more →BLRXConfidential property: Not to be used without written authorization from Health Science Communications. Corporate Presentation March 2017 2 Forward - Looking Statements This presentation contains "forward - looking state
Confidential property: Not to be used without written authorization from Health Science Communications. Corporate Presentation March 2017 2 Forward - Looking Statements This presentation contains "forward - looking statements." These statements include words like "may," "expects
Read more →BLRXBioLineRx Reports Second Quarter 2016 Financial Results
TEL AVIV, Israel, Aug. 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter
Read more →BLRXBioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological...
TEL AVIV, Israel, May 19, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences. An abstract titled "Cl
Read more →BLRXBioLineRx Reports First Quarter 2016 Financial Results
TEL AVIV, Israel, May 17, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended Ma
Read more →BLRXBioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
TEL AVIV, Israel, March 23, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation. The Phase 2
Read more →BLRXBioLineRx to Report Annual 2015 Results on March 10, 2016
TEL AVIV, Israel, March 3, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its audited annual financi
Read more →BLRXBioLineRx to Present at 2016 BIO CEO & Investor Conference in New York on February 8
TEL AVIV, Israel, February 1, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsk
Read more →BLRXBioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
TEL AVIV, Israel, January 25, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the Eu
Read more →BLRXBioLineRx Announces Collaboration with MSD to Investigate the Combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer
TEL AVIV, Israel, January 12, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's
Read more →BLRXBioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
TEL AVIV, Israel, January 4, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky
Read more →BLRXBioLineRx Ltd. Announces Closing of $15 million Private Placement to Institutional Investors Jerusalem, Israel
Ltd. Announces Closing of $15 million Private Placement to Institutional Investors Jerusalem, Israel, February 27, 2012 - BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), announced today that it has closed its previously announced $15 million private placement to healthcare-focused U
Read more →BLRXBioLineRx to place $15 million in securities with Institutional Investors Jerusalem, Israel
to place $15 million in securities with Institutional Investors Israel - February 15, 2012 - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (the "Company"), a biopharmaceutical development company, announced today it has entered into definitive agreements with healthcare-focused U.
Read more →BLRXBioLineRx Acquires Exclusive License Rights From Algen for Cancer Therapeutic BL-7030
JERUSALEM, May 17, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that it has acquired the rights to compound BL-7030, a novel molecule for targeted cancer therapy, from Algen, which received exclusive rights from Yissum, the Hebrew University of Jerusalem. BL-70
Read more →BLRXBioLineRx Reacquires Rights to Leading Schizophrenia Drug Candidate BL-1020
JERUSALEM, May 11, 2011 (GLOBE NEWSWIRE) -- BioLineRx Ltd. (TASE:BLRX), a biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies, announced today the signing of an agreement
Read more →BLRXBioLineRx Receives Notice of Allowance From USPTO for Patent Covering BL-1020 Drug for Treatment of Schizophrenia
JERUSALEM, April 4, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application covering the BL-1020 drug and its use for the treatment of schizophrenia
Read more →BLRXBioLineRx Announces Positive Topline Results for BL-1020, a First in Class GABA Enhanced Antipsychotic for the Treatment of Schizophrenia
JERUSALEM, Israel, Sept. 14, 2009 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today topline results from its phase 2b EAGLE (Effective Antipsychosis via GABA Level Enhancement) study assessing the efficacy, safety and tolerability of BL-1020, conducted under a US FDA IND
Read more →Competitive Position
How BLRX ranks across every disease it competes inCompetitive Position is a premium feature
See how BLRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial